<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01311570</url>
  </required_header>
  <id_info>
    <org_study_id>B080910</org_study_id>
    <nct_id>NCT01311570</nct_id>
  </id_info>
  <brief_title>Study Assessing the Safety and Therapeutic Effect of Buprenorphine in MDD Patients</brief_title>
  <official_title>A Single Center, Open Label, Dose-titration, add-on Study Assessing the Feasibility, Safety and Therapeutic Effect of Buprenorphine in Adult Patients With Diagnosis of Major Depression.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shalvata Mental Health Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shalvata Mental Health Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to assess the therapeutic effect of Buprenorphine in
      MDD population.

      The secondary objectives of this study are to assess the therapeutic effect, the feasibility
      and safety of buprenorphine in a MDD population.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>October 2012</start_date>
  <primary_completion_date type="Anticipated">February 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary objective of this study is to assess the therapeutic effect of Buprenorphine in MDD population.</measure>
    <time_frame>from baseline to day 42 [end of Buprenorphine treatment]</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The secondary objectives of this study are to assess the therapeutic effect, the feasibility and safety of buprenorphine in a MDD population.</measure>
    <time_frame>from baseline to day 42 [end of Buprenorphine treatment]</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>Buprenorphine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Buprenorphine</intervention_name>
    <description>In the first 2 weeks all subjects will enter into a dose titration phase, starting with minimum dosage of 1mg/day Buprenorphine gradually increasing to 4-8 mg/day according to tolerance and clinical benefit.
From week 3 to week 8, all subjects are prescribed Buprenorphine sublingually, OID in a stable dosage according to the decision of the treating physician.</description>
    <arm_group_label>Buprenorphine</arm_group_label>
    <other_name>subutex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Outpatients and inpatients

          -  Men and women 18-68 years of age.

          -  Primary DSM-IV diagnosis of Major Depression, single or recurrent episode confirmed by
             the Structured Clinical Interview for the DSM-IV (SCID-IV), with the additional
             requirements of a current episode ≥4 weeks and CGI-S ≥4.

          -  Total HDRS-21 ≥20 and Item 1 score ≥2 at the screening visit.

          -  The patient did not respond to at least one antidepressant medication given for an
             accepted dose and duration.

          -  If currently taking Benzodiazepines, the patient must be clinically appropriate to
             discontinue treatment with those agents, and able to tolerate no benzodiazepines
             during the study period.

          -  Capable and willing to provide informed consent

          -  Able to adhere to the treatment schedule.

        Exclusion Criteria:

          -  Depression secondary to a general medical condition.

          -  History of substance abuse or dependence within the past 6 month (except nicotine and
             caffeine).

          -  All antidepressant medications, must have been in stable dosage for at least 6 weeks
             prior to entry into the study, with no anticipation of change over the duration of the
             study.

          -  Use of any medication(s) listed on the Excluded medication list within the time that
             mansion for each medication on the list.

          -  Any psychotic disorder (lifetime), including schizoaffective disorder, or major
             depression with psychotic features • Bipolar disorder • Eating disorder

          -  Presence (within 12 months of baseline) of a personality disorder (such as antisocial,
             schizotypal, histrionic, borderline, narcissistic) as assessed by the investigator to
             be primary, causing a higher degree of distress or impairment than MDD.

          -  Use of a Monoamine Oxidase Inhibitor (MAOI) within 2 weeks of the screening visit

          -  Use of a CYP3A4 Inhibitors and CYP3A4 Inducers within 2 weeks of screening visit.

          -  Present suicidal risk as assessed by the investigator or significant suicide risk
             based on HDRS-21 item 3 score of 3 or 4 or a history of attempted suicide in the last
             6 month

          -  Known or suspected pregnancy

          -  Women who are breast-feeding

          -  Women of childbearing potential and not using a medically accepted form of
             contraception when engaging in sexual intercourse.

          -  Patients with severe respiratory insufficiency or asthma - anticipation require
             examination of pulmonologist.

          -  Patients with severe hepatic or renal insufficiency.

          -  Patients with history of head injury, increased intracranial pressure, hypotension,
             prostatic hypertrophy or urethral stenosis- anticipation require examination of
             neurologist.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>68 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ziv carmel, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>shalvata medical health center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ziv carmel, M.D</last_name>
    <phone>00-972-9-7478644</phone>
    <email>zivca@clalit.org.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shalvata Medical Health Center</name>
      <address>
        <city>Hod-Hasharon</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ziv carmel, M.D.</last_name>
      <phone>00-972-9-7478644</phone>
      <email>zivca@clalit.org.il</email>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 9, 2011</study_first_submitted>
  <study_first_submitted_qc>March 7, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2011</study_first_posted>
  <last_update_submitted>September 23, 2012</last_update_submitted>
  <last_update_submitted_qc>September 23, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 25, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Buprenorphine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

